Geron Co. (NASDAQ:GERN - Get Free Report) CEO John A. Scarlett purchased 12,500 shares of Geron stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average cost of $1.76 per share, with a total value of $22,000.00. Following the acquisition, the chief executive officer now directly owns 12,500 shares of the company's stock, valued at $22,000. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Geron Trading Down 2.8 %
Shares of NASDAQ GERN opened at $1.71 on Tuesday. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -5.34 and a beta of 0.53. Geron Co. has a 12-month low of $1.46 and a 12-month high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock's 50 day simple moving average is $2.93 and its 200 day simple moving average is $3.76.
Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The business had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. Equities research analysts expect that Geron Co. will post -0.25 EPS for the current year.
Institutional Trading of Geron
Hedge funds have recently made changes to their positions in the stock. SBI Securities Co. Ltd. bought a new stake in shares of Geron in the 4th quarter worth approximately $28,000. Integrated Wealth Concepts LLC acquired a new stake in Geron in the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. acquired a new stake in Geron in the 4th quarter valued at approximately $45,000. Fifth Lane Capital LP acquired a new stake in Geron in the 4th quarter valued at approximately $53,000. Finally, Readystate Asset Management LP acquired a new stake in Geron in the 3rd quarter valued at approximately $58,000. Institutional investors own 73.71% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts recently commented on GERN shares. B. Riley downgraded Geron from a "buy" rating to a "neutral" rating and reduced their price target for the company from $3.50 to $2.00 in a report on Thursday, February 27th. HC Wainwright downgraded Geron from a "buy" rating to a "neutral" rating in a report on Wednesday, February 26th. Needham & Company LLC reduced their price target on Geron from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Stifel Nicolaus reduced their price target on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Finally, Barclays reaffirmed an "overweight" rating and set a $4.00 target price (down previously from $9.00) on shares of Geron in a report on Thursday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $5.68.
Read Our Latest Stock Analysis on GERN
About Geron
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
